A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib ; volume:21 ; number:1 ; day:4 ; month:3 ; year:2022 ; pages:1-17 ; date:12.2022
Molecular cancer ; 21, Heft 1 (4.3.2022), 1-17, 12.2022
- Creator
-
Li, Ke-xin
Wu, Hui-yang
Pan, Wan-ying
Guo, Meng-qi
Qiu, De-zhi
He, Yan-jie
Li, Yu-hua
Yang, Dong-Hua
Huang, Yu-xian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-022-01541-9
- URN
-
urn:nbn:de:101:1-2022053119134250746747
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Ke-xin
- Wu, Hui-yang
- Pan, Wan-ying
- Guo, Meng-qi
- Qiu, De-zhi
- He, Yan-jie
- Li, Yu-hua
- Yang, Dong-Hua
- Huang, Yu-xian
- SpringerLink (Online service)
Other Objects (12)
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Correction: A novel approach for relapsed/refractory FLT3mut+acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Management of relapsed-refractory diffuse large B cell lymphoma
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma